LOD, Israel, March 4, 2019 /CNW/ -- Panaxia in collaboration with the Israeli Pharmaceutical company "Rafa", has begun a clinical research of medical cannabis concentrates for inhalation. This new method of delivery will increase accessibility mainly in cancer patients treated with long-term pharmaceutical cannabis (such as sublingual tablets), and suffering from acute cancer pain who prefer to avoid smoking cannabis. The research has currently begun, and the products are due for distribution in pharmacies during 2019 under Rafa's medical cannabis brand.
The Israeli pharmaceutical company Panaxia Pharmaceutical Industries, has announced a clinical trial for registration purposes at the Ministry of Health, to examine the biological availability of delivering medical cannabis via a metered-dose inhaler.
The inhaler includes an attached vaporizer to which the patient adds the measured dose of cannabis extract for inhalation. The cannabis extract includes a precise dose of active ingredients.
Panaxia's advanced medical cannabis products, marketed by Rafa Pharmaceuticals, will be tested as part of the clinical trial and its registration will revolutionize the way medical cannabis is used for treating patients. The great potential of cannabis, delivered via a metered-dose inhaler, is its designation for palliative cancer patients, which are eligible for treatment with medical cannabis and suffer from symptoms of cancer pain (BTcP).
According to Dr. Itay Gur-Aryeh, M.D, Director of the Pain Unit at Sheba Hospital, Tel Hashomer, "Every clinical research that helps manage treatment using medical cannabis is important. Delivering treatment via inhalation is characterized by a quicker response time than oral or sublingual tablets."
According to Dr. Dadi Segal, Panaxia CEO, "The clinical trial is performed as part of the registration procedure of the new products which we are about to launch in Israel this year, in collaboration with Rafa. Through access to cannabis inhalers, and subject to a medical specialist's recommendation, we strive to help more patients suffering from acute pain. The inhaler will provide patients that are unable or unwilling to smoke, the right to be treated consistently and precisely."
Anat Savion, Rafa CEO, adds, "This innovative product is an additional method of delivery of medical cannabis products which we are intending to launch. The future of treatment with medical cannabis is the ability to match treatment to each patient in the best possible way."
About Panaxia Israel
Panaxia Israel is part of the pharmaceutical group of the Segal family, operating for over four decades, and manufacturing over 600 different pharmaceutical products, which it distributes in over 30 countries. Panaxia was founded by Dr. Dadi Segal, Dr.Eran Goldberg and Assi Rotbart, LL.b, and constitutes the Group's cannabis division. In addition, the sister-division of North America manufactures over 60 pharmaceutical products based on medical cannabis, including sublingual tablets, oral tablets, oils, inhalers, and more, intended to treat conditions such as post-traumatic stress, cancer, chronic pains, epilepsy, anorexia, burns, and many other medical conditions. Panaxia employs around 90 employees and all clinical experiments are conducted by the company.
For further info: Steve Levy, Email – [email protected]/ Tel (305) 933-4646
SOURCE Panaxia Pharmaceutical Industries
Related Links
Original Press Release: newswire.ca
